$Hims & Hers Health(HIMS.US) got three days of free advertising, and the dust has settled. It's tough for the investors who got scared and sold at a loss.
U.S. telehealth company Hims & Hers Health: Since launching its compounded oral semaglutide formulation on its platform, it has engaged in constructive communication with various industry stakeholders. The company has decided to discontinue offering services related to this treatment.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
